BioCentury
ARTICLE | Clinical News

Celgene reports Phase II data for Revlimid in lymphoma

June 21, 2013 12:48 AM UTC

Celgene Corp. (NASDAQ:CELG) presented data on Thursday at the Malignant Lymphoma meeting in Lugano from a pair of Phase II trials evaluating the company's multiple myeloma (MM) drug Revlimid lenalidomide in lymphoma patients. In the Phase II ALLIANCE (CALGB-50803) trial to treat previously untreated follicular lymphoma, once-daily oral Revlimid plus rituximab led to an overall response rate (ORR) in 54 evaluable patients of 92.6%, including 39 complete responses and 11 partial responses, plus two cases of stable disease. The trial was sponsored by NIH's National Cancer Institute. In a separate Phase II trial to treat diffuse large B cell lymphoma (DLBCL), Revlimid plus R2-CHOP chemotherapy (rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) led to an ORR in 63 evaluable patients of 98%, including a complete response rate of 74%. The 18-month progression-free survival (PFS) rate was 66%.

Celgene markets Revlimid in nearly 70 countries, including the U.S. and EU countries, in combination with dexamethasone to treat relapsed or refractory MM in patients who have received one or more prior therapy. In the U.S., the thalidomide analog is also approved to treat patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) with a 5q chromosomal deletion and for relapsed or refractory mantle cell lymphoma (MCL). ...